Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office
McKinsey
Moodys
Covington
Chubb
US Department of Justice
Merck
Daiichi Sankyo

Generated: July 21, 2018

DrugPatentWatch Database Preview

LENVIMA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Lenvima patents expire, and when can generic versions of Lenvima launch?

Lenvima is a drug marketed by Eisai Inc and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and seven patent family members in thirty countries.

The generic ingredient in LENVIMA is lenvatinib mesylate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the lenvatinib mesylate profile page.
Summary for LENVIMA
International Patents:107
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 65
Clinical Trials: 9
Patent Applications: 12
DailyMed Link:LENVIMA at DailyMed
Drug patent expirations by year for LENVIMA
Generic Entry Opportunity Date for LENVIMA
Generic Entry Date for LENVIMA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LENVIMA
Synonyms for LENVIMA
4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-(3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
4-(3-chloro-4-(N'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide
4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide
4-{3-Chloro-4-[(Cyclopropylcarbamoyl)amino]phenoxy}-7-Methoxyquinoline-6-Carboxamide
417716-92-8
4CA-0485
716C928
A1-04306
A825653
ABP000863
AC-25047
AK175809
AKOS025401742
AN-6642
AOB87766
AS-16203
BC252209
BCP9000633
BCPP000247
BDBM50331094
CHEBI:85994
CHEMBL1289601
CS-0109
CTK1D4875
D09919
D0R0FO
DB-070219
DB09078
DTXSID50194605
E 7080
E-7080
E-7080, E7080
E7080
E7080 (Lenvatinib)
E7080, E 7080
E7080/E-7080
EE083865G2
ER-203492-00
EX-A249
FT-0700727
GTPL7426
HE068062
HE342379
HMS3244A07
HMS3244A08
HMS3244B07
HMS3654A14
HY-10981
J-513372
KB-78118
Kisplyx
KS-00000638
Lenvatinib
Lenvatinib (E7080)
Lenvatinib (USAN/INN)
Lenvatinib [USAN:INN]
Lenvatinib mesilate
Lenvatinib; E7080
LenvatinibE7080)
LEV
MFCD16038644
MLS006011239
MolPort-009-679-469
NCGC00263198-01
QCR-115
RS0099
s1164
SC-87813
SCHEMBL864638
SMR004702999
SYN1038
UNII-EE083865G2
WOSKHXYHFSIKNG-UHFFFAOYSA-N
ZINC3816292

US Patents and Regulatory Information for LENVIMA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for LENVIMA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,612,092 Nitrogen-containing aromatic derivatives ➤ Sign Up
8,372,981 Nitrogen-containing aromatic derivatives ➤ Sign Up
7,973,160 Nitrogen-containing aromatic derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for LENVIMA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015039 Lithuania ➤ Sign Up PRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
/2015 Austria ➤ Sign Up PRODUCT NAME: LENVATINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON ODER EIN HYDRAT DAVON; REGISTRATION NO/DATE: EU/1/15/1002/001-002 (MITTEILUNG) 20150601
2015000083 Germany ➤ Sign Up PRODUCT NAME: LENVATINIB ODER EINES SEINER PHARMAZEUTISCH AKZEPTABLEN SALZE ODER EINES SEINER HYDRATE; REGISTRATION NO/DATE: EU/1/15/1002/001-002 20150528
2015 00053 Denmark ➤ Sign Up PRODUCT NAME: LENVATINIB, ELLER ET FARMAKOLOGISK ACCEPTABELT SALT DERAF ELLER ET HYDRAT DERAF, HERUNDER LENVATINIB MESILAT; REG. NO/DATE: EU/1/15/1002/001-002 20150601
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Julphar
McKinsey
Chinese Patent Office
Cerilliant
Baxter
Queensland Health
Harvard Business School
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.